Pridopidine for ALS

(PREVAiLS Trial)

This trial tests whether pridopidine can help treat amyotrophic lateral sclerosis (ALS) and slow its progression. ALS affects nerve cells in the brain and spinal cord, causing muscle weakness and disability. Participants will take either pridopidine or a placebo (a look-alike pill with no active drug) for about a year, then switch to pridopidine for another year. The trial seeks individuals with definite or probable ALS who have had symptoms for 18 months or less and can swallow pills. As a Phase 3 trial, it represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial does not specify if you need to stop taking your current medications, but you cannot use medications that prolong the QT interval (a measure of heart rhythm). It's best to discuss your current medications with the trial team.

Research has shown that pridopidine is generally safe for people. In earlier studies, its safety profile matched that of a placebo. Falls were the most common side effect, affecting about 28% of those taking pridopidine and 29% of those on a placebo. Serious side effects were rare but included falls, thoughts of self-harm, head injuries, and swallowing problems. Overall, the data indicate that pridopidine's safety is comparable to placebo treatments.¹²³⁴⁵

Researchers are excited about Pridopidine for ALS because it offers a novel mechanism of action compared to current treatments like riluzole and edaravone. Unlike these standard treatments, which primarily aim to slow disease progression, Pridopidine targets the Sigma-1 receptor, which is thought to help protect nerve cells from damage. This unique approach has the potential to not only slow the progression of ALS but also improve motor function and quality of life for patients. By focusing on neuroprotection, Pridopidine could offer a new avenue for managing ALS symptoms more effectively.

Research suggests that pridopidine, which participants in this trial may receive, might help slow the progression of ALS (amyotrophic lateral sclerosis). One study found that pridopidine slowed the decline of an important function score by 32% over 24 weeks, particularly in individuals with early-stage ALS. Another study showed that pridopidine reduced levels of a nerve damage marker, neurofilament light chain (NfL), by 40% in patients with fast-progressing disease. While some results are promising, not all studies showed significant effects on the main outcomes. Overall, pridopidine shows potential, especially for early-stage or rapidly progressing ALS cases, but more research is needed to confirm its effectiveness.¹²³⁴⁶